Description: Reunion is a leader in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The Company’s lead asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. Reunion is also developing the FT-200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.
Home Page: www.fieldtriphealth.com
REUN Technical Analysis
30 Duncan Street
Toronto,
ON
M5V 2C3
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Hannan Fleiman | Co-Founder & Non-Independent Director |
| Mr. Mujeeb Jafferi | CO-Founder & COO |
| Dr. Nathan Bryson B.Sc., Ph.D. | Chief Scientific Officer |
| Mr. Gregory T. Mayes Esq., J.D. | Pres, CEO & Director |
| Mr. Edward F. Smith CPA | Chief Financial Officer |
| Mr. Matt Emmer | Director of Operations & Bus. Devel. |
| Curtis Weber | Gen. Counsel & Corp. Sec. |
| Mr. Stephan Cote | Head of Quality |
| Ms. Vicki Reed | Chief Growth Officer |
| Dr. Michael Verbora M.B.A., M.D. | Sr. VP & Medical Director |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4939 |
| Price-to-Sales TTM: | 2.8033 |
| IPO Date: | 2021-07-29 |
| Fiscal Year End: | March |
| Full Time Employees: | 194 |